source
- Novo Nordisk lifts 2026 guidance as Wegovy sales surge in Q1Novo Nordisk reported its first‑quarter results, noting that sales and operating profit are expected to decline less than previously forecast. The company said adjusted sales fell between 4% and 1…
- Novo Nordisk shares rise as Wegovy updates improve earnings outlookNovo Nordisk reported that recent data on its obesity drug Wegovy were less negative than expected, helping the company’s earnings. The improved outlook lifted Novo Nordisk’s share price, narrowin…